Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Colby who wrote (2196)	3/15/1999 4:00:00 PM
From: Jay	Respond to of 4140

CNBC's Joe Kernan (sp?) says VISX will be on "Squak Box" tomorrow @ around 9:10 est.

To: Colby who wrote (2196)	3/15/1999 5:24:00 PM
From: Joe	Respond to of 4140

Colby, "A few optometrists ..." "1. The market sunrise is after is not big enough. Why would a doctor buy a machine that treats only hyperopia when he/she can buy a machine that treats both?" It is interesting that an optometrist might say this. Usually it is an ophthalmologist that would make that statement and be challenged by the optometrist. The reason is that it is usually the optometrist that sees the hyperopes, particularly the presbiopes. The ophthalmologist usually sees more myopes. The fact is that there are more hyperopes than myopes by a fairly large percentage. Hyperopes, more specifically mild hyperopes, do not need glasses because the eye, at least in a young person, can accomodate to correct the problem. As the eye gets older though, the lens becomes harder and people lose their ability to accomodate. This makes reading difficult. Hence reading glasses. The principal study that people refer to with respect to the distribution of vision in the population is the Framingham Study. It is well known to many medical professionals. The data shows the market for SNRS LTK is big, very big. Now why would some buy LTK when they already have and excimer for LASIK or PRK? Most clinicians want to do the best medicine they can for their patients. Further, assuming SNRS puts together an effective public information campaign, patients will demand LTK over the invasive procedures. This will be further incentive for the practicioner that doesn't necessarily care about doing the best medicine he can. For an ophthalmologist that wants to participate in refractive surgery, this will give him the opportunity with a lower entry fee, especially if he is doing refractive procedures in a center and wants to retain a higher percentage of the fee charged to the patient. "2. Certain eyes (having to do with the shape of the lense) work better with the Sunrise laser. Others don't take to the procedure to well. He said they have not perfected their technology yet." I have not heard this one before. Anyone have any input??? Maybe what they are talking about is simple hyperopia as contrasted to hyperopia with astigmatism. If that is what they are talking about, LTK technology is capable of and will be able to correct astigmatism. I am told the new model LTK system that will be shown at ASCRS next month has features which should make correction of astigmatism more effective. The company will need to perform clinical trials to show effectiveness. (ASCRS is American Society of Cataract and Refractive Surgery.) "3. There has been a fair amount of regression." Anyone having looked at the early clinical data done by Summit Technology would say this. And while Sunrise early clinical data was greatly improved over that from Summit, there was still some regression. The technique being used for the past year or two is greatly improved and the amount of regression is only a little greater than the change in vision that one encounters without treatment. Further if there is mild regression, if it occurs over a period of three to five years, it means that people will be retreated. This is similar to getting a new pair of glasses. I hope this has been helpful. We are all anxiously awaiting our baby VISX's birth. Joe

To: Colby who wrote (2196)	3/15/1999 6:04:00 PM
From: majormember	Read Replies (2) \| Respond to of 4140

Colby, I thought a repost of the S & P "Stock of the Week" report might clear up a few of your questions on market penetration. Could only find the one when SNRS was on the BB....they did another report when it hit Nasdaq.............Regards, Skane ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 4/14/98 10:00 am. SUNRISE TECHNOLOGIES (SNRS 6.60 - OTC- BULLETIN BOARD). This company has the potential to revolutionize the world of ophthalmology and eye care. SNRS develops Holmium laser-based systems which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic conditions. The CorneaSparing laser thermal keratoplasty (LTKT) System is a non-contact simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of focus due to natural aging), and overcorrection resulting from PRK and LASIK treatments for myopia. The system is in Phase III clinical trials in the U.S. and is currently in use in Europe and the Americas. SNRS started clinical trials for hyperopia way back in late '93, but, because of poor management, made little progress. However, things changed in mid '96 when C. Russell Trenary III joined the co. Trenary is now President and CEO. He had more than 15 years of experience in the ophthalmic industry, coming over from Allergan, where he was Senior VP/GM of the $180 million ophthalmic surgical devices group. Since mid '96, the co. has divested its dental operations to focus exclusively on laser surgery, and has built an experienced management team with over 100 years of ophthalmic and laser experience. The market for SNRS's procedure is enormous. the co. is initially focusing on the market for simple hyperopia, or individuals between +0.75 and +2.50 diopters. Statistically, 31% of the initial targeted market over 40 years old in the Americas and Western Europe, or about 200 million people, are candidates for the SNRS procedure. According to CEO Trenary, the co. intends to sell these lasers for $200,000. the ophthamolgists will charge about $1000 per eye with SNRS getting $100 of that. Projected net margins are 90% for the procedure and 60% for the machine. just a 5% market penetration rate would yield per-procedure fees of $2 billion per year, and that does not include sales of the laser machines. Trenary believes the Phase III study will be wrapped up by June '98. According to V.P. of Clinical and Regulatory affairs, Jeannie Gifford Cecka, the co. has treated over 450 eyes and the results have shown a very high safety profile. Dr. Alan Aker, Aker-Kasten Cataract and Laser Institute, tells MarketScope that he has personally performed over 100 of these procedures and says the results have been incredible, has had no problems with the procedure, and marvels about how happy his patients are after the procedure. CEO Trenary tells MarketScope that the co. anticipates FDA approval as early as mid '99 and as late as mid 2000. The procedure itself is quite simple, takes about 2 seconds, is non-invasive, offers quick visual recovery, and there is little to no pain involved. The Sunrise Corneal Shaping System directs small amounts of heat to eye tissue, outside of the central vision zone, thereby shrinking collagen in a few small spots, and reshaping the cornea to correct refractive errors of the eye. there is simultaneous delivery, in a variable pattern, of up to 8 energy balanced and homogeneous infrared laser beams at a wavelength of 2.1 micrometers. the energy in the laser beams is adjusted to achieve an appropriate temperature and depth profile when directed onto a patient cornea. the depth of penetration varies from 50% to 70% of the corneal thickness. the reason this system works is that collagen undergoes thermal modification of its fibers (contracts) when the fibers reach a critical temperature of 58 to 75 degrees Celsius. it is the unique property of collagen that can be used to change the curvature of the cornea. The laser system is very attractive to not only patients but to ophthalmologists. according to Dr. Aker, ophthalmologists have been hit hard by reductions in cataract fees and will seize upon this technology to offset their losses. they can perform many procedures each day, training is fairly simple, and maintenance for the laser system is minimal. current laser systems for nearsightedness cost up to $500,000 with maintenance running up to $100,000/year. plus the procedures are invasive and the safety risks are much higher than SNRS's. As a vote of confidence, many ophthalmologists have taken big equity stakes in the co. To demonstrate some of the progress that SNRS has made over the last year, we start with an announcement made on 7/30/97 that the co. received conditional approval from the FDA to include the second eye in clinical trials 6 months after the first eye is done. on 8/12/97, the co. got conditional FDA approval to expand the trials to an additional 100 patients in their hyperopia study. 11/19/97 received FDA approval to move into Phase III studies for treating hyperopia. on 12/11/97, SNRS formed a Scientific Advisory Board comprised of leading ophthalmic surgeons from around the world. 1/27/98 completed $9.35 million private financing of which 80% of the money came from ophthalmologists who have seen the clinical data or have experience using the system for treating hyperopia. on 2/24/98, SNRS got conditional FDA approval to treat the second eye on the same day. and on 3/24/98, the co. got FDA approval to begin a study to treat patients who are overcorrected after having a myopic excimer laser procedure resulting in induced hyperopia. On a technical basis, the stock is also quite appealing. SNRS recently broke out to all-time highs on extremely heavy volume. the stock is currently consolidating recent gains on lighter volume and looks poised to take out the intra-day high of $7.5 on its way to $8 to $10. We believe the stock is extremely attractive for speculative accounts on a short term basis and has the potential to be a blockbuster over the next couple of years. /Mark Arbeter